Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Medivir AB logo — Improving life for cancer patients through transformative dr...

Medivir AB

Improving life for cancer patients through transformative drugs

Founded 1988 Sweden Sweden 46 employees Post-IPO Equity Total: $50.80M Biotechnology, Pharmaceutical

General Information

Company Name Medivir AB
Founded Year 1988
Location Sweden Sweden
Employees 46
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Medivir AB. To contact Medivir AB, visit medivir.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Medivir AB compare?

A PDF of Medivir AB and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Medivir AB soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Medivir AB

Medivir AB is a Swedish company focused on biotechnology and pharmaceuticals. The company, founded in 1988, operates with the slogan "Improving life for cancer patients through transformative drugs". Medivir's primary goal is to develop innovative drugs, particularly targeting areas with high unmet medical needs, such as cancer. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a targeted chemotherapy designed to selectively treat liver cancer cells while minimizing side effects. Collaborations and partnerships play a significant role in Medivir's business model, with the drug development being carried out either independently or in partnership. The company's shares (ticker: MVIR) are listed on Nasdaq Stockholm's Small Cap list. The most recent investment in Medivir AB was a kr20.00M post-IPO equity investment on 22 January 2024. The details of the investors involved in this specific investment round are not provided. Overall, Medivir AB presents an interesting proposition for potential investors, particularly with its focus on addressing unmet medical needs in the oncology space through targeted drug development.

Business keywords: pharmaceuticals, oncology, drug development, biotech, cancer treatment, research-based, protease inhibitors, nucleotide science, clinical development, partnerships, Nasdaq Stockholm, smart chemotherapy, specialty care, medical innovation, Nordic market

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity kr20.00M -
22 Jan 2024
Post IPO Equity €30.80M -
09 Dec 2010

Medivir AB Alternatives & Competitors

View All Alternatives
Medivir AB vs
Ascelia Pharma AB
Ascelia Pharma AB Sweden

Ascelia Pharma is an oncology-dedicated orphan drug company listed on Nasdaq Stockholm under the tic...

Post-IPO Equity
16 employees
Biotechnology, Health Care
Medivir AB vs
Oncopeptides AB (publ)
Oncopeptides AB (publ) Sweden

Oncopeptides is a global biotech company focused on research & development of therapies for difficul...

Grant
97 employees
Biotechnology, Pharmaceutical
Compare Medivir AB vs Oncopeptides AB (publ)
Medivir AB vs
Apollomics
Apollomics United States

We are a biopharmaceutical company committed to the discovery and development of mono- and combinati...

Post-IPO Equity
26 employees
Biotechnology, Health Care
View all alternatives

FAQ About Medivir AB

Improving life for cancer patients through transformative drugs
Medivir AB was founded in 1988.
Medivir AB is headquartered in Sweden.
Medivir AB operates in Biotechnology and Pharmaceutical. Its work centres on pharmaceuticals, oncology, drug development and biotech.
Medivir AB has approximately 46 employees.
Medivir AB has completed 2 funding rounds, raising a total of $50.80M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Medivir AB include Ascelia Pharma AB, Oncopeptides AB (publ), Apollomics, Semafore Pharmaceuticals, Coeptis Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Medivir AB and Ascelia Pharma AB are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Medivir AB, https://bouncewatch.com/company/medivir-ab, updated 30 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout